Octagam 100 mg/ml raztopina za infundiranje स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

octagam 100 mg/ml raztopina za infundiranje

octapharma (ip) ltd., - polispecifični imunoglobulin, humani - raztopina za infundiranje - polispecifični imunoglobulin, humani 100 mg / 1 ml - humani imunoglobulini za intravaskularno aplikacijo

Octagam 100 mg/ml raztopina za infundiranje स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

octagam 100 mg/ml raztopina za infundiranje

octapharma (ip) ltd., - polispecifični imunoglobulin, humani - raztopina za infundiranje - polispecifični imunoglobulin, humani 100 mg / 1 ml - humani imunoglobulini za intravaskularno aplikacijo

Suliqua 100 enot/ml + 33 mikrogramov/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

suliqua 100 enot/ml + 33 mikrogramov/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku

sanofi-aventis groupe - insulin glargin, liksisenatid - raztopina za injiciranje - insulin glargin 100 e. / 1 ml; liksisenatid 33 e. / 1 ml - insulin glargin in liksizenatid

Suliqua 100 enot/ml + 50 mikrogramov/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

suliqua 100 enot/ml + 50 mikrogramov/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku

sanofi-aventis groupe - insulin glargin, liksisenatid - raztopina za injiciranje - insulin glargin 100 e. / 1 ml; liksisenatid 50 e. / 1 ml - insulin glargin in liksizenatid

Octagam 100 mg/ml raztopina za infundiranje स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

octagam 100 mg/ml raztopina za infundiranje

polispecifični imunoglobulin, humani - raztopina za infundiranje - polispecifični imunoglobulin, humani 100 mg / 1 ml - humani imunoglobulini za intravaskularno aplikacijo

Sitagliptin Accord यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

sitagliptin accord

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Galvus यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

galvus

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.